Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination drug** composed of five active pharmaceutical ingredients: **pancreatin**, **oryz-aspergillus enzyme**, **acarbose**, **metformin**, and **glimepiride**. - **Pancreatin** and **oryz-aspergillus enzyme** are digestive enzymes designed to enhance gastrointestinal digestive function, commonly used in the management of dyspepsia and postprandial discomfort. Clinical studies show that the combined use of oryz-aspergillus enzyme and pancreatin tablets is effective in improving symptoms of dyspepsia and functional digestive disorders, with a favorable safety profile[1][3][7]. - **Acarbose** is an alpha-glucosidase inhibitor, which delays carbohydrate absorption in the gut, thereby blunting postprandial blood glucose spikes. It is commonly used to improve glycemic control in type 2 diabetes, especially in combination with other oral antidiabetic agents[2][4][8]. - **Metformin** is a biguanide that reduces hepatic glucose production and increases peripheral glucose uptake and utilization. It is the first-line therapy for type 2 diabetes due to its glycemic efficacy, weight neutrality, and cardiovascular safety[2][4][6]. - **Glimepiride** is a sulfonylurea that stimulates pancreatic beta cells to secrete insulin, leading to a reduction in blood glucose levels. It is frequently combined with metformin and/or other oral antidiabetic agents in type 2 diabetes for synergistic glycemic effect[6][8]. This combination targets both **digestive dysfunction (such as dyspepsia, maldigestion, and functional gastrointestinal symptoms)** and **hyperglycemia in type 2 diabetes mellitus**. The rationale is to address both gastrointestinal comfort and comprehensive glycemic control, particularly in elderly patients or those with concomitant digestive and metabolic disorders. While individual pairings of these ingredients are widely used and studied, there is limited evidence on the fixed-dose combination of all five in a single pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pancreatin + oryz-aspergillus enzyme + acarbose + metformin + glimepiride.